By Ted Barrett, PhD – Senior Director, Pharmacology
In biotech, teams often equate the accumulation of preclinical experiments, endpoints, and validation work with progress. That instinct makes sense, especially in a field rooted in scientific rigor. But in today’s capital-constrained environment, that mindset is shifting. The question is no longer how much preclinical data can be generated, but whether that data meaningfully informs a decision that moves a drug development program forward.
This distinction sits at the core of decision-driven drug development. Rather than building large datasets and hoping value emerges, decision-driven drug development begins by defining the intended outcome. What milestone are we working toward? Who needs to be convinced? What specific question must be answered to justify the next step? With that clarity, data becomes less about volume and more about purpose.
Investors and regulators are not evaluating drug development programs on how much data they produce, but on the clarity and relevance of that data in assessing risk and value potential. This shift in expectations places a premium on thoughtful study design, where each experiment is deliberately constructed to address a defined objective.
The hidden cost of more data
It’s easy to see how teams lose this focus. Scientific curiosity plays an important role, particularly in early-stage companies or academic spinouts where a deep understanding of mechanism can feel critical. At the same time, there is a natural inclination to reduce uncertainty by collecting as much information as possible.
However, this tendency can lead to diminishing returns, as additional data consumes both time and capital while introducing layers of complexity that can cloud – rather than clarify – the path forward.
These challenges are particularly acute for smaller biotech companies, which are often centered around a single asset and operate with limited financial flexibility. Unlike large pharma that can pursue multiple parallel strategies, smaller teams must be far more selective in how they deploy resources. Their success depends on the ability to reach clear go or no-go decisions quickly, with each step tied to program advancement.
Within this environment, “failing fast” takes on a different meaning. An early negative signal can provide valuable clarity that prevents further investment in a program that is unlikely to succeed. This approach not only conserves resources for the individual company but also supports the broader ecosystem by allowing capital to flow toward more promising opportunities.
Different constraints, different strategies
The distinct strategic paths between large pharmaceutical companies and smaller biotech firms highlights why this matters. Large organizations follow established development playbooks and have the resources to iterate across multiple programs. Their approach often focuses on reducing risk, which can justify larger datasets over longer timelines as they refine and optimize potential therapies.
By contrast, early-stage biotech companies must align every study with a specific milestone, often tied to funding events or key inflection points. In these environments, the value of data (preclinical or otherwise) lies in its ability to unlock the next stage of development. This creates a very different set of incentives, where efficiency and focus are not simply beneficial, but essential.
When this alignment breaks down, the impact is clear. Teams design studies that are too complex, chase secondary questions, or seek funding that does not match investor expectations. They can become overly focused on mechanistic detail at the expense of practical decision-making, generating data that is interesting but not purposeful.
Designing studies that drive decisions
A better approach begins with clear intent. Before beginning preclinical research, and again at each phase of preclinical development, teams should establish whether the primary goal is to demonstrate proof of concept, attract investment, or prepare for regulatory interaction, all while still seamlessly integrated into an overarching milestone driven approach. This ensures that the data serves a purpose within the broader development strategy.
From there, the emphasis shifts to identifying the most informative experiment that can address the key question. This does not mean sacrificing scientific rigor but rather focusing it where it matters most.
For example, in an inhaled drug program, an early milestone may not involve demonstrating therapeutic efficacy—it might be that the drug can be successfully formulated, generated into an inhalable aerosol and delivered at a therapeutically relevant dose. If that foundational requirement cannot be met, the program is unlikely to move forward. If it can, that result could provide sufficient confidence to justify continued investment.
Top 5 questions to ask before generating more data
A decision-driven approach often comes down to asking the right questions before starting the next phase of work.
1. What specific decision will this study enable?
2. Who needs to be convinced by this data, and what do they care about?
3. What is the next milestone, and what is the most efficient way to reach it?
4. How does this phase of development align with future regulatory expectations?
5. Are we prepared to act on the results, regardless of the outcome?
From data generation to decision engine
Ultimately, the shift away from prioritizing data volume and toward emphasizing decision quality reflects an evolution of the biotech industry. Success depends on the ability to generate the right insights at the right time, enabling smarter choices and more efficient pathways to the clinic.
When approached thoughtfully, this approach conserves resources and strengthens the overall narrative of a program—and it builds confidence among investors, regulators, and key stakeholders.